US Stock MarketDetailed Quotes
VSTM Verastem
- 4.1900
- -0.2500-5.63%
Close Dec 20 16:00 ET
- 4.3500
- +0.1600+3.82%
Post 19:35 ET
186.48MMarket Cap-1.33P/E (TTM)
4.5500High4.1900Low1.81MVolume4.3700Open4.4400Pre Close7.69MTurnover5.95%Turnover RatioLossP/E (Static)44.51MShares14.220052wk High16.83P/B127.29MFloat Cap2.100052wk Low--Dividend TTM30.38MShs Float225.8400Historical High--Div YieldTTM8.11%Amplitude2.1000Historical Low4.2570Avg Price1Lot Size
Heat List
US
Overall
Symbol
Price
% Chg
No Data
Verastem Stock Forum
erastem Oncology Provides a Clinical Update for Ramp 203 Trial in Advanced Kras G12C Mutant Non-Small Cell Lung Cancer! Seen no dose limiting toxicities
If you had bought on 10/31 my last comment, you'd be up 30% now, grats
Pretty damn good run so far. I only managed to hop on in Sept.
Verastem Oncology Completes Rolling NDA Submission to the FDA for Avutometinib Plus Defactinib as a Treatment for Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
Verastem Oncology (VSTM) has completed its rolling New Drug Application (NDA) to the FDA for avutometinib plus defactinibcombination therapy for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC). The company is seeking accelerated approval and priority review, with a potential FDA ap...
Robust overall response rates observed (31% overall, 44% in KRAS mutant, 17% in KRAS wild-type) in patients whose cancer had progressed despite prior treatment with chemotherapy and/or MEK inhibitors and/or bevacizumabPatients on avutometinib and defactinib achieved a median progression free survival of more than one year (12.9 months)...
Verastem Oncology Presents Positive Updated RAMP 201 Data for Avutometinib and Defactinib Combination in Recurrent Low-Grade Serous Ovarian Cancer at the International Gynecologic Cancer Society (IGCS) 2024 Annual Meeting
Verastem Oncology presented updated data from the Phase 2 RAMP 201 trial evaluating avutometinib and defactinibcombination in recurrent low-grade serous ovarian cancer (LGSOC) at the IGCS 2024 Annual Meeting. Key findings include:
- 31% overall response ...
No comment yet